Robert Klein is a scientific and business leader with three decades of biotechnology experience. His biotechnology career started at Genentech, first as a research associate and then, after obtaining his PhD, as a postdoctoral fellow and a scientist. During his five years at Genentech, Dr. Klein directed their preclinical development of glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease (PD). He subsequently worked at a number of biotechnology startups over a two-decade period taking on roles of increasing responsibility in the areas of neuroscience drug development, genomics, and diagnostics. These include Deltagen, Rinat Neuroscience, where he led the Alzheimer’s and PD efforts, Amnestix, again leading their Alzheimer’s program, iKaryos Diagnostics, Complete Genomics, Genomics Medicine Ireland, Alkahest and, most recently, as CEO and cofounder of Addition Therapeutics. Dr. Klein received his PhD in biology from MIT and his AB in biochemistry from the University of California, Berkeley.
Development of a Safe and Efficient Method to Treat Parkinson’s Disease Using RNA-based Gene Therapy